Carboxylic Acid-Doxorubicin Liposome (PEGylated) (CAT#: CLBD010LY)

Description
This formulation is Doxorubicin Liposome (PEGylated) with the carboxyl group, which can be activated by EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide) and react with sulfo-NHS (N-hydroxysulfosuccinimide) to produce a significantly more stable and more soluble active intermediate (NHS ester). The intermediate can covalently conjugate to the amine group on the proteins, peptides or antibodies through displacement of sulfo-NHS group by amine.
Lipid Composition
HSPC, Cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-Carboxylic Acid
Encapsulated Drug
Doxorubicin
Buffer
PBS, pH 6.0
Storage
Store in dark at +4°C and do not freeze
Size
100 nm
Quantity
5mL (available in lyophilized powder)
Molecular Structure
Download
DataSheet MSDS
FAQs Customer Reviews Related Sections
  1. What is the primary application of carboxylic acid-doxorubicin liposomes?

    These liposomes are used primarily for targeted cancer therapy, leveraging the enhanced permeability and retention effect to deliver doxorubicin more effectively and with reduced systemic toxicity.

  2. How does the carboxylic acid functionality benefit these liposomes?

    The carboxylic acid group on these liposomes can be activated for conjugation with targeting molecules, enhancing the delivery of doxorubicin to specific cancer cells.

  3. What advantages does PEGylation offer to these liposomes?

    PEGylation helps to extend the circulation time of the liposomes in the bloodstream, reducing the immunogenicity and enhancing the stability of the formulation.

  4. Are there any specific cancer types for which these liposomes are particularly effective?

    These liposomes are especially beneficial in the treatment of cancers known to respond well to doxorubicin, such as breast, ovarian, and certain types of lung cancer.

  5. Can the carboxylic acid-doxorubicin liposomes be used in combination therapies?

    Yes, they can be used in combination with other therapeutic agents to potentially enhance efficacy and overcome resistance in various cancer treatments.

  • Enhanced Stability and Solubility
    Creative Biolabs' carboxylic acid-doxorubicin liposomes have revolutionized our research with their enhanced stability and solubility, enabling more precise drug delivery experiments.
  • Pioneering Precision in Drug Delivery
    The carboxylic acid-doxorubicin liposomes from Creative Biolabs are a game changer, providing targeted drug delivery with reduced systemic toxicity, essential for our oncology projects.
  • Creative Biolabs' Innovation in Cancer Research
    Utilizing Creative Biolabs' liposomes has significantly improved the therapeutic index in our cancer research, thanks to their innovative carboxylic acid-doxorubicin composition.
  • Superior Drug Retention and Release
    These liposomes exhibit superior drug retention and release properties, which are critical in achieving the desired outcomes in our studies on drug resistance.
  • Creative Biolabs: Leaders in Liposomal Delivery
    Thanks to Creative Biolabs, our research into novel delivery systems has advanced significantly, with their carboxylic acid-doxorubicin liposomes leading the way.

Click the button below to contact us or submit your feedback about this product.

For Research Use Only. Not For Clinical Use

Online Inquiry

Advertisement